Secondary analysis of the NAVIGATOR trial (1,059 patients with severe uncontrolled asthma; 165 with nasal polyps): more tezepelumab than placebo recipients reported better sleep, activity and exertion tolerance at week 52, more so with nasal polyps.
Secondary analysisn = 1,059
Lugogo et al. Tezepelumab's effects on patient-reported symptoms in severe asthma, overall and with history of comorbid chronic rhinosinusitis with nasal polyps (CRSwNP)